1、Michael L Wang, et al., Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers, NEJM Evid. 2022 Jan; 2、https://www.merck.com/news/mercks-investigational-zilovertamab-vedotin-in-combination-with-r-chp-demonstrates...
1、Michael L Wang, et al., Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers, NEJM Evid. 2022 Jan; 2、https://www.merck.com/news/mercks-investigational-zilovertamab-vedotin-in-combination-with-r-chp-demonstrates-complete-response-rate-of-100-at-1-75-mg-kg-dose-in...
1、Michael L Wang, et al., Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers, NEJM Evid. 2022 Jan; 2、https://www.merck.com/news/mercks-investigational-zilovertamab-vedotin-in-combination-with-r-chp-demonstrates-complete-response-rate-of-100-at-1-75-mg-kg-dose-in...
1、Michael L Wang, et al., Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers, NEJM Evid. 2022 Jan; 2、https://www.merck.com/news/mercks-investigational-zilovertamab-vedotin-in-combination-with-r-chp-demonstrates-complete-response-rate-of-100-at-1-75-mg-kg-dose-in...
2、https://www.merck.com/news/mercks-investigational-zilovertamab-vedotin-in-combination-with-r-chp-demonstrates-complete-response-rate-of-100-at-1-75-mg-kg-dose-in-phase-2-trial-of-previously-untreated-patients-with-diff/
2、https://www.merck.com/news/mercks-investigational-zilovertamab-vedotin-in-combination-with-r-chp-demonstrates-complete-response-rate-of-100-at-1-75-mg-kg-dose-in-phase-2-trial-of-previously-untreated-patients-with-diff/